We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
Bromocriptine Mesylate Tablets, USP 2.5mg (Padagis, USA)
Section 19A approved medicine
Bromocriptine Mesylate Tablets, USP 2.5mg (Padagis, USA)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 516
Phone
1800 181 060
Approved until
Status
Current
Medicines in short supply/unavailable
PARLODEL bromocriptine 2.5mg (as mesilate) tablet blister pack - ARTG 13367
Indication(s)
- Treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. Precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. Where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, bromocriptine is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated.
- Adjunctive therapy in the management of acromegaly when:
- The patient refuses surgery and/or radiotherapy
- Surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months
- A manifestation of the acromegaly needs to be brought under control pending surgery and/or radiotherapy.
- Idiopathic or post-encephalitic Parkinson's disease. It should be noted that data are not yet sufficient to evaluate the role of bromocriptine in treating early Parkinsonism.
Images
